SCHEMBL7705995

SCHEMBL7705995

O=C(Nc1ccccc1)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 4/20 0.71
CA9 Q16790 2/20 0.64
ENPP3 O14638 1/20 0.64
CA2 P00918 1/20 0.64
ENPP1 P22413 1/20 0.64
ENPP2 Q13822 1/20 0.64
CA12 O43570 1/20 0.63
MEN1 O00255 1/20 0.63
KMT2A Q03164 1/20 0.63
NPSR1 Q6W5P4 1/20 0.63
SMN1; SMN2 Q16637 2/20 0.62
EPHX2 P34913 1/20 0.61
CYP2D6 P10635 1/20 0.60
MAPT P10636 1/20 0.60
CNR2 P34972 2/20 0.60
HPGD P15428 1/20 0.59
STS P08842 1/20 0.58
CNR1 P21554 1/20 0.54
NPC1 O15118 1/20 0.54
LMNA P02545 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31552469 0.93 P2RX7 (0.60) P2RX7CA9ENPP3CA2ENPP1
SCHEMBL19072437 0.89 P2RX7 (0.57) P2RX7CA9ENPP3CA2ENPP1
SCHEMBL28424952 0.84 P2RX7 (0.52) P2RX7CA9ENPP3CA2ENPP1
SCHEMBL25447578 0.84 P2RX7 (0.77) P2RX7NPSR1EPHX2CYP2D6MAPT
SCHEMBL1549023 0.84 P2RX7 (0.73) P2RX7CA9ENPP3CA2ENPP1
SCHEMBL1947902 0.83 SMN1; SMN2 (0.66) P2RX7CA9ENPP3CA2ENPP1
SCHEMBL5092145 0.83 P2RX7 (0.67) P2RX7MEN1KMT2ASMN1; SMN2EPHX2
SCHEMBL7827905 0.83 EPHX2 (0.67) P2RX7CA9CA12MEN1KMT2A
SCHEMBL8303597 0.83 P2RX7 (0.72) P2RX7CA9ENPP3CA2ENPP1
SCHEMBL3321310 0.83 CA9 (0.64) P2RX7CA9ENPP3CA2ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170283347-A1 NOVEL ADAMANTANE DERIVATIVE COMPOUND AMOREPACIFIC CORPORATION (KR) 2017-10-05 US claimed
CN-107207416-A Novel adamantine alkane derivatives compound 株式会社爱茉莉太平洋 2017-09-26 CN claimed
EP-3187486-A1 NOVEL ADAMANTANE DERIVATIVE COMPOUND Amorepacific Corporation (KR) 2017-07-05 EP claimed
US-6348625-B1 TREATING CORRESPONDING CARBOXYLIC ACID FUNCTIONAL GROUP WITH N,N-DIETHYL-1,1,2,3,3,3-HEXAFLUOROPROPYLAMINE FOLLOWED BY AMMONIA ANDERSON GLORIA LONG (US) 2002-02-19 US claimed
US-12240857-B2 Adamantane derivatives for the treatment of filovirus infection ARISAN THERAPEUTICS INC. (US) 2025-03-04 US disclosed
EP-3187486-B1 NOVEL ADAMANTANE DERIVATIVE COMPOUND AMOREPACIFIC CORP (KR) 2023-10-18 EP disclosed
CN-115556446-A Decorative film and method for producing decorative molded body using same 日本聚丙烯株式会社 2023-01-03 CN disclosed
CN-115556441-A Decorative film and method for producing decorative molded body using same 日本聚丙烯株式会社 2023-01-03 CN disclosed
CN-111386185-A Decorative film and method for producing decorative molded body using same 日本聚丙烯株式会社 2020-07-07 CN disclosed
US-10696611-B2 Adamantane derivative compound AMOREPACIFIC CORPORATION (KR) 2020-06-30 US disclosed
US-10696611-B2 Adamantane derivative compound AMOREPACIFIC CORPORATION (KR) 2020-06-30 US disclosed
CN-107207416-B Novel adamantane derivative compound 株式会社爱茉莉太平洋 2020-02-07 CN disclosed
WO-2017127306-A1 ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION ARISAN THERAPEUTICS (US) 2017-07-27 WO disclosed
EP-3187486-A1 NOVEL ADAMANTANE DERIVATIVE COMPOUND Amorepacific Corporation (KR) 2017-07-05 EP disclosed
EP-3187486-A1 NOVEL ADAMANTANE DERIVATIVE COMPOUND Amorepacific Corporation (KR) 2017-07-05 EP disclosed
US-7220532-B2 Chemical amplification type resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-22 US disclosed
US-7220532-B2 Chemical amplification type resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-22 US disclosed
US-6348625-B1 TREATING CORRESPONDING CARBOXYLIC ACID FUNCTIONAL GROUP WITH N,N-DIETHYL-1,1,2,3,3,3-HEXAFLUOROPROPYLAMINE FOLLOWED BY AMMONIA ANDERSON GLORIA LONG (US) 2002-02-19 US disclosed
US-4053509-A ADAMANTANE-CARBOXAMIDES OR CYCLOPROPANE-CARBOXAMIDES, CNS DRUGS ON SCHERING CORPORATION (US) 1977-10-11 US disclosed
US-3944675-A Substituted aryl and aralkyl amides in the treatment of parkinsonism SCHERING CORPORATION (US) 1976-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240857-B2 Adamantane derivatives for the treatment of filovirus infection IFNAR1, MEP1B, MEP1A P2RX7 1347/4885CA9 4751/4885ENPP3 1037/4885
US-10696611-B2 Adamantane derivative compound ADAM8, BACE1, CYP17A1 P2RX7 2139/4885CA9 623/4885ENPP3 1563/4885
US-20170283347-A1 NOVEL ADAMANTANE DERIVATIVE COMPOUND ADAM8, CYP17A1, ADAM10 P2RX7 2069/4885CA9 758/4885ENPP3 1589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.